https://www.taxtmi.com/news?id=62637 The LANDMARK trial was a prospective, randomized, multicenter, open label non inferiority study of 768 patients across 31 sites in 16 countries that found the balloon expandable Myval THV series non inferior to contemporaneous balloon expandable and self expandable THV platforms on a one year composite clinical efficacy endpoint (freedom from all cause mortality, all stroke, and procedure or valve related hospitalization), with event free rates of 87.0% for Myval and 86.9% for each comparator, and plans for ten year follow up. en-us Tue, 25 Nov 2025 11:16:03 +0530 Tue, 25 Nov 2025 11:16:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=62637 The LANDMARK trial was a prospective, randomized, multicenter, open label non inferiority study of 768 patients across 31 sites in 16 countries that found the balloon expandable Myval THV series non inferior to contemporaneous balloon expandable and self expandable THV platforms on a one year composite clinical efficacy endpoint (freedom from all cause mortality, all stroke, and procedure or valve related hospitalization), with event free rates of 87.0% for Myval and 86.9% for each comparator, and plans for ten year follow up. News - Tue, 25 Nov 2025 11:16:03 +0530 https://www.taxtmi.com/news?id=62637